With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift toward oral GLP-1 drugs. While Novo leverages its first-mover advantage with ...
Incomplete and inaccurate verbiage in communications with the doctor is causing one delay after another. And they show no sign of caring if the patient gets their medication or not. NO COMMUNICATION ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results